75.11 -0.01 (-0.01%)
After hours: 4:05PM EDT
|Bid||75.12 x 800|
|Ask||75.15 x 900|
|Day's Range||74.63 - 75.67|
|52 Week Range||63.68 - 95.93|
|PE Ratio (TTM)||89.43|
|Forward Dividend & Yield||0.76 (0.97%)|
|1y Target Est||N/A|
Starboard Value disclosed that last week it bought $30.2 million in additional shares of Perrigo (PRGO), a maker of over-the-counter and generic drugs. Starboard now has total ownership of 10 million Perrigo shares, a stake of 7.3%, and is now that company's second-largest shareholder, according to S&P Capital IQ. The buying by Starboard seems to have been spurred by weakness after the company cut guidance.
Insiders at a flooring products maker and a REIT returned to the buy window this week. Conventional wisdom says that insiders and 10-percent owners really only buy shares of a company for one reason — they believe the stock price will rise and want to profit. Perrigo Company plc (NYSE: PRGO) saw one of its directors buy 400,000 shares of this Dublin-based health care products maker.
Does the share price for Perrigo Company plc (NYSE:PRGO) reflect it’s really worth? Today, I will calculate the stock’s intrinsic value using the discounted cash flow (DCF) method. If youRead More...
On May 14, Teva (TEVA) stock increased ~5.5% on the news of the expected delay in the FDA approval for rival Perrigo’s (PRGO) generic version of Teva’s asthma inhaler ProAir. On May 14, Teva stock closed at a trading price of $20.38 per share.
Aspen Pharmacare Holdings Ltd.’s infant formula business has drawn interest from companies including Reckitt Benckiser Group Plc and Perrigo Co., as the largest African drugmaker evaluates options for the business, people familiar with the matter said. Family-owned French dairy group Lactalis and Australia’s iNova Pharmaceuticals, controlled by Pacific Equity Partners and Carlyle Group LP, are also weighing offers for a stake in the business, according to the people. Aspen shares soared the most in two months, trading 3.6 higher at 262.49 rand as of 2:03 p.m. in Johannesburg.
Teva jumped Monday after competitor Perrigo said it expects the FDA to delay its generic version of Teva's asthma inhaler called ProAir.
Stock movements reflect premarket trading. The electric auto maker has moved closer to setting up its first overseas car plant by registering a company in Shanghai. : Alphabet's Waymo LLC has hired a senior Tesla executive who was the auto maker's main technical contact with U.S. safety investigators.
The Dow Jones Industrial Average appears set for a higher open this morning after President Donald Trump tweeted that he's working to get China's ZTE "back into business" following U.S. sanctions, a sign that a trade war might not be imminent. Dow Jones Industrial Average futures have risen 54 points, or 0.2%, while S&P 500 futures have ticked up 0.1%, and Nasdaq Composite futures have advanced 0.2%. Tigress Financials's Ivan Feinseth notes that not only is Trump working with China on ZTE, but that China has reopened an antitrust review of Qualcomm’s (QCOM) potential acquisition of NXP Semiconductor (NXPI).
Perrigo Co. said it expects U.S. regulators will reject its application for what one analyst had a called its must-have asthma inhaler, a generic version of Teva Pharmaceutical Industries Ltd.’s ProAir. Perrigo said in a statement Friday that it was made aware that it would receive a Complete Response Letter from the U.S. Food and Drug Administration, delaying its plans to start selling the inhaler in the fourth quarter of this year. Perrigo’s stock fell, losing 4.4 percent after the markets closed.
U.S. health regulators have rejected Perrigo’s generic version of Teva Pharmaceutical Industries’ ProAir inhalation aerosol, Perrigo said.
Shares of Perrigo Co. Plc fell more than 3% late Friday after the pharma company pared its 2018 guidance as it won't launch a generic version of an asthma medication in the fourth quarter as planned. As a result of the delay with the generic version of ProAir, "the company no longer expects to achieve the approximately $0.09 per share benefit that was included in its 2018 reported and adjusted earnings per share guidance range," Perrigo said. Perrigo in March said it expected 2018 per-share earnings to be in the range of $2.24 to $2.64, and adjusted EPS guidance to be in the range of $5.05 to $5.45 for the year.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Perrigo (PRGO) misses earnings estimates but exceeds revenue expectations in Q1. The company reiterates its revenue and adjusted earnings outlook for 2018.
Some pharma stocks are on the rise today, following earnings and Shire's (SHPG) $62 billion takeover deal, but the goodwill didn't spread to all regions of the sector. Valeant Pharmaceuticals International (VRX) delivered a beat-and-raise first quarter, saying it earned 89 cents a share on revenue of $2 billion, while analysts expected EPS of 60 cents on revenue of $1.95 billion. For the full year, it now sees revenue of $8.15 billion to $8.35 billion, up from its previous $8.1 billion-$8.3 billion range, and above the $8.23 billion consensus estimate.
Generics drug companies Amneal Pharmaceuticals LLC and Impax Laboratories Inc have won U.S. antitrust approval to merge, the U.S. Federal Trade Commission said on Friday. Under the terms of the proposed settlement, the FTC said ANI Pharmaceuticals Inc will acquire seven products, Perrigo Company Plc will acquire Impax's rights to two products that it had partnered with Impax to manufacture and sell, and G&W Laboratories Inc will acquire Impax's marketing rights to one product that G&W manufactures for Impax. Adding to their woes, U.S. retail pharmacies, including Wal-Mart Stores Inc and Walgreens Boots Alliance Inc , are wielding more leverage when buying such drugs, leading to price erosion.
The U.S. Federal Trade Commission said on Friday it would require Impax Laboratories Inc and privately held Amneal Pharmaceuticals LLC to divest rights to 10 generic medications as a condition of their merger. The FTC said that under the terms of the proposed settlement ANI Pharmaceuticals Inc will acquire seven products, Perrigo Company Plc will acquire Impax's rights to two products that it had partnered with Impax to manufacture and sell, and G&W Laboratories Inc will acquire Impax's marketing rights to one product that G&W manufactures for Impax.
U.S. prosecutors were nearing their first charges against generic-drug companies in a nearly four-year-old criminal probe into a possible price-fixing, Bloomberg reported, citing people familiar with the matter. Soaring drug prices from both branded and generic drugmakers have sparked outrage and investigations in the past, with President Donald Trump last year calling it "getting away with murder". In October, Reuters reported https://www.reuters.com/article/us-usa-generics/u-s-states-allege-broad-generic-drug-price-fixing-collusion-idUSKBN1D0201 a lawsuit on the price-fixing case accused 18 companies, including Mylan and Teva Pharmaceutical, and named 15 medicines.
Eli Lilly and Co. (LLY) reported revenues of ~$5.7 billion for 1Q18 today, reflecting 9% growth from 1Q17. The company beat Wall Street analysts’ estimates for earnings-per-share (or EPS) and revenues in 1Q18 and reported EPS of $1.34 on revenues of ~$5.7 billion, compared to an estimated EPS of $1.14 on revenues of ~$5.5 billion.
Perrigo Company plc (NYSE:PRGO) is trading with a trailing P/E of 98.5x, which is higher than the industry average of 22.2x. While this makes PRGO appear like a stock toRead More...
Perrigo Company (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
A review of Jeffrey Smith's investing strategy and take a look inside Starboard Value's stock portfolio. Largest holdings include Perrigo Company PLC (NYSE: PRGO ), Altaba Inc (Nasdaq: AABA ), and Marvell ...
CNBC's Meg Tirrell reports that Perrigo no longer expects to get FDA approval for generic ProAir in the fourth quarter of 2018.